What is HC Wainwright’s Forecast for TLSI Q3 Earnings?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for TriSalus Life Sciences in a research report issued on Wednesday, September 9th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.12) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. HC Wainwright also issued estimates for TriSalus Life Sciences’ Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.31) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at $0.09 EPS, FY2029 earnings at $0.57 EPS and FY2030 earnings at $1.02 EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The business had revenue of $11.41 million during the quarter, compared to analyst estimates of $10.27 million.

A number of other research firms also recently issued reports on TLSI. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.67.

TriSalus Life Sciences Trading Down 1.3%

NASDAQ TLSI opened at $4.70 on Friday. The company has a market cap of $289.43 million, a P/E ratio of -3.62 and a beta of 0.44. TriSalus Life Sciences has a 12 month low of $2.20 and a 12 month high of $7.95. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. The company has a 50-day moving average of $4.75 and a 200-day moving average of $4.33.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of TLSI. JPMorgan Chase & Co. raised its holdings in TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of TriSalus Life Sciences in the second quarter worth $47,000. Cura Wealth Advisors LLC acquired a new stake in shares of TriSalus Life Sciences in the second quarter worth $36,000. Invesco Ltd. purchased a new position in shares of TriSalus Life Sciences in the 4th quarter valued at $72,000. Finally, Abel Hall LLC purchased a new position in shares of TriSalus Life Sciences in the 4th quarter valued at $73,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

Key Stories Impacting TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: HC Wainwright’s forecasts point to improving profitability over time. The firm projects EPS losses of $0.31 for fiscal 2026 and $0.28 for fiscal 2027, followed by positive EPS of $0.09 in 2028, $0.57 in 2029 and $1.02 in 2030. This creates a long-term growth narrative for investors. TriSalus Life Sciences analyst estimates
• Positive Sentiment: The analyst expects quarterly losses to narrow from $0.12 per share in the third quarter of 2026 to $0.02 per share in the fourth quarter of 2027, suggesting gradual operating improvement.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.